Headlines about Bellicum Pharmaceuticals (NASDAQ:BLCM) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bellicum Pharmaceuticals earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.2255064197817 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
Shares of Bellicum Pharmaceuticals opened at $7.99 on Friday, MarketBeat.com reports. The stock has a market cap of $345.98 million, a price-to-earnings ratio of -2.81 and a beta of 0.46. Bellicum Pharmaceuticals has a 1 year low of $8.18 and a 1 year high of $8.36. The company has a debt-to-equity ratio of 0.53, a quick ratio of 6.75 and a current ratio of 6.75.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.02. The firm had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.08 million. analysts predict that Bellicum Pharmaceuticals will post -2.52 earnings per share for the current year.
Several equities analysts recently commented on the company. Cantor Fitzgerald set a $10.00 target price on Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 13th. SunTrust Banks dropped their target price on Bellicum Pharmaceuticals to $18.00 and set a “buy” rating on the stock in a report on Wednesday, January 31st. Wells Fargo lowered Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 target price on the stock. in a report on Wednesday, January 31st. ValuEngine lowered Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Citigroup increased their target price on Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the company a “hold” rating in a report on Friday, February 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $17.98.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.